Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SeaStar Medical’s SEC disclosures can feel like running a clinical trial of your own. The company’s 10-K dives deep into extracorporeal immunomodulation science, while 8-Ks detail pivotal FDA feedback and capital raises that affect the ICU ticker overnight. Finding the cash runway, dilution terms, or hyperinflammation trial data in hundreds of pages isn’t easy.
That’s why Stock Titan pairs every filing with AI-powered summaries that translate complex biotech jargon into plain English. Want the SeaStar Medical quarterly earnings report 10-Q filing without wading through accounting footnotes? Our algorithm highlights burn rate and R&D spend in seconds. Need to watch SeaStar Medical insider trading Form 4 transactions? Real-time alerts flag each executive stock move, so you never miss a signal.
Browse every disclosure—from the SeaStar Medical annual report 10-K simplified to 8-K clinical milestone updates—alongside concise explanations that answer the questions investors actually ask: how new data may impact FDA timelines, whether fresh capital changes dilution math, or why a director just bought shares. With instant access to:
- Form 4 feeds for SeaStar Medical executive stock transactions Form 4
- AI digests of each 10-Q earnings report and 10-K annual filing
- SeaStar Medical proxy statement executive compensation insights
- SeaStar Medical 8-K material events explained the moment they post to EDGAR
Stop searching, start understanding—SeaStar Medical SEC filings explained simply so you can focus on decisions, not deciphering documents.
SeaStar Medical Holding Corporation launched an at‑the‑market offering of up to $2,279,989 of common stock under its S‑3 shelf, with H.C. Wainwright as sales agent. Sales may be made on Nasdaq or otherwise at prevailing prices. Wainwright will receive a 3.0% cash commission on gross sales, and will be deemed an underwriter for these transactions.
The company intends to use net proceeds for general corporate purposes. As of October 10, 2025, ICU last traded at $0.5716 and its listed warrants at $0.0301. SeaStar notes its public float was $42,019,639 (33,886,805 non‑affiliate shares at $1.24) and that it remains subject to Form S‑3 I.B.6 limits; it sold $11,726,556 over the prior 12 months. Nasdaq has notified the company of $1.00 minimum bid non‑compliance; SeaStar has until January 27, 2026 to regain compliance. If all ATM shares were sold at $0.5716, common stock outstanding would rise to up to 38,085,204 shares; the actual number depends on sale prices.
SeaStar Medical Holding Corp (ICU) Form 3 filed by Bradford K. Towne reports beneficial ownership of 15,500 shares of common stock. The filing is an initial statement under Section 16 and reflects stock awards rather than open-market purchases.
The 15,500 shares include 5,000 restricted stock units (RSUs) from an April 12, 2024 grant of 8,000 RSUs that vest monthly through February 2028 and 7,500 RSUs granted April 1, 2025 that vest in three equal tranches on April 1, 2026, 2027 and 2028. Towne is identified as the issuer's Principal Accounting Officer. The event date triggering the report is 08/26/2025 and the form is signed on 09/09/2025.
SeaStar Medical Holding Corp (ICU) director Kenneth Van Heel reported open-market purchases totaling 35,000 shares across two days. On 08/26/2025 he acquired 25,000 shares at a weighted-average price of $0.8899, increasing his direct holdings to 39,400 shares. On 08/27/2025 he acquired 10,000 shares at a weighted-average price of $0.8565, raising his direct holdings to 49,400 shares.
The Form 4 shows these were non-derivative purchases and that no derivative securities were reported. The filing was submitted by an attorney-in-fact on 08/28/2025.
SeaStar Medical insider purchase: Chief Medical Officer Kevin Chung purchased 10,000 shares of SeaStar Medical Holding Corp (ICU) on 08/22/2025 at a reported price of $0.80 per share, increasing his beneficial ownership to 58,184 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or additional remarks were reported.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting collective beneficial ownership of 1,466,096 shares of SeaStar Medical Holding Corp common stock, equal to 4.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that Armistice exercises voting and investment power over the Master Fund's holdings; Mr. Boyd, as managing member, is similarly reported. The submission characterizes the position as held in the ordinary course of business and not for the purpose of changing or influencing control.
SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01. The amendment states it makes no changes to the substance of the original report.
The original report furnished a press release as Exhibit 99.1 announcing the company's financial condition and results for the three and six months ended June 30, 2025.
SeaStar Medical Holding Corporation (ICU) reported early commercial sales of its pediatric SCD product QUELIMMUNE, recognizing $338 thousand in revenue for the quarter and $631 thousand for the six months ended June 30, 2025. Gross profit was $311 thousand for the quarter and $604 thousand for six months; cost of goods sold was $27 thousand. The company recorded a net loss of $2.0 million for the quarter and $5.8 million for the six months, with a weighted-average share base of 11.33 million and basic and diluted net loss per share of $(0.18) and $(0.58), respectively.
The balance sheet shows $6.3 million in cash and $8.4 million in total assets as of June 30, 2025, and an accumulated deficit of $145.3 million. Management states it does not believe existing cash is sufficient to fund operations for 12 months and discloses substantial doubt about going concern. The filing details multiple 2025 equity financings (February, June, ATM proceeds) and subsequent July/August 2025 registered offerings, and notes receipt of a Nasdaq notice for bid-price noncompliance with a cure period to January 27, 2026.
FAQ
What is the current stock price of SeaStar Medical Holding (ICU)?
What is the market cap of SeaStar Medical Holding (ICU)?
